1st research shows the breast cancer drug market to be currently a $10.2 billion market. Roche's drug Avastin has also left a void in some of that pie after being pulled from the U.S. market. Emerging drugs like Celldex's will be welcomed as clearly emerging therapies are needed and will account for one quarter of the overall market.for breast cancer treatments according to a study World News reported on.
Oncologists have indicated that efficacy, including improvement in time to disease progression, is one of the greatest unmet needs in metastatic breast cancer. Celldex's drug CDX-011 is the focus here an is an antibody drug conjugate used to treat metastatic breast cancer and melanoma indication! Results showed CDX-011 delayed tumor growth and prolonged survival in patients with advanced and and this aggressive form of breast cancer.
The median overall survival almost doubled in the CDX-011 treated patients!!! These will lead to a Celldex FDA meeting ASAP. This will expedite the next news release on the topic. Once a larger study group confirms this the unmet need will put pressure on getting this drug out to patients with few good options if any.
This stock will soar on the next agreement with the FDA on a coarse of action.
For these reasons a target of $50 in 2013 is initiated and a rating of: "MARKET OUTPERFORM" given.
Use some due diligence and you will probably agree and come to the same conclusion that this review is actually conservative,